CVE-T 0.23 IAC-Q 0.72 DNTL-T 0.07 CLX-LON 0 KSPI-Q -0.31 TMHC-N 0.76
Daily Stock Opinions and Ratings
Stockchase Opinions

Paul MacDonald Biogen IDEC Inc. BIIB-Q COMMENT May 03, 2019

Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
Paul MacDonaldPaul MacDonald
Unknown
Unlock Rating
$231.180

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Biogen IDEC Inc.(BIIB-Q)

Nov 26, 2020

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)

The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$241.750

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biogen IDEC Inc.(BIIB-Q)

Feb 11, 2021
Very high risk, very high reward. Seeing competition on its core drugs. Its Alzheimer's drug didn't get a great reception. Somewhere around June 7 the regulator will rule on this drug. Could be impacted 30% up or 50% down. Not for him.
Paul MacDonaldPaul MacDonald
No
Unlock Rating
$279.135

Stock price when the opinion was issued

biotechnology pharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Biogen IDEC Inc.(BIIB-Q)

Jun 08, 2021

(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.

The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$389.705

Stock price when the opinion was issued

biotechnology pharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Biogen IDEC Inc.(BIIB-Q)

Aug 17, 2021
(A Top Pick Nov 26/20, Up 43%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB is progressing well. We now recommend trailing up the stop (from $305) to $320. If triggered this would all but guarantee a investment return over 29%, when including the previous recommendation to cover half.
The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$346.375

Stock price when the opinion was issued

biotechnology pharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Biogen IDEC Inc.(BIIB-Q)

Sep 09, 2021
(A Top Pick Nov 26/20, Up 32.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB has triggered its stop at $320. We recommend covering the position at this time. We will look for another entry point when value is justified again.
The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$300.700

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biogen IDEC Inc.(BIIB-Q)

Mar 07, 2022
They own almost nothing in the Health Care space and Biotech is particularly weak.
David BurrowsDavid Burrows
Unknown
Unlock Rating
$206.000

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Biogen IDEC Inc.(BIIB-Q)

Feb 27, 2023

The FDA figure who was key in getting their Alzheimer's drug recently left the FDA, but all the Alzheimer's plays declined except Biogen.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
N/A

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Biogen IDEC Inc.(BIIB-Q)

May 03, 2023

A great stock that whose Alzheimer drug will do well. (See also Eli Lilly.) Shares bounced along, but now picked up momentum.

Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Unknown
Unlock Rating
$311.080

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Biogen IDEC Inc.(BIIB-Q)

Nov 27, 2023

They haven't launched their weight-loss drug yet, but the company's expects something big from it next year. The problem is that BIIB is lumped in with the general drug group.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$228.870

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biogen IDEC Inc.(BIIB-Q)

May 10, 2024

Not impressed with products. Competitors out performing. 

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$221.605

Stock price when the opinion was issued

biotechnology pharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

CNQ-T 0.03$43.28
FDX-N 2.57$222.18
RCI.B-… 0.54$36.46
JNJ-N 0.2$155.23
BCE-T 0.43$30.25

Today's Top Picks

CVE-T 0.23$18.77
IAC-Q 0.72$36.7
DNTL-T 0.07$8.61
CLX-LO… 0$51.2
KSPI-Q -0.31$85.62

Popular Articles

Latest Sell Signals

PFE-N 0.62$23.97
META-Q -3.65$694.06
UPS-N 1.06$99.31
WING-Q 1.31$376.13
TSLA-Q 13.44$308.58

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Mike Vinokur

Mike Vinokur

MV Wealth Partners

Jason Del Vicario

Jason Del Vicario

HollisWealth

Javed Mirza

Javed Mirza

Canaccord Genuity

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica